Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03847649
Title Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

Advanced Solid Tumor

Therapies

Durvalumab

Durvalumab + Prednisone

Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Cross Cancer Institute Recruiting Edmonton Alberta T6G 1Z2 Canada Details
BCCA - Cancer Centre for the Southern Interior Recruiting Kelowna British Columbia V1Y 5L3 Canada Details
BCCA - Vancouver Cancer Centre Recruiting Vancouver British Columbia V5Z 4E6 Canada Details
Regional Health Authority B, Zone 2 Recruiting Saint John New Brunswick E2L 4L2 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton Ontario L8V 5C2 Canada Details
Grand River Regional Cancer Centre Recruiting Kitchener Ontario N2G 1G3 Canada Details
Ottawa Hospital Research Institute Recruiting Ottawa Ontario K1H 8L6 Canada Details
University Health Network Recruiting Toronto Ontario M5G 2M9 Canada Details
Windsor Regional Cancer Centre Recruiting Windsor Ontario N8W 2X3 Canada Details
CHUM-Centre Hospitalier de l'Universite de Montreal Recruiting Montreal Quebec H2X 3E4 Canada Details
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) Recruiting Quebec City Quebec G1J 1Z4 Canada Details
Saskatoon Cancer Centre Recruiting Saskatoon Saskatchewan S7N 4H4 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field